508-93-0
Chemical Structure
Evomonoside
- CAS No.: 508-93-0
- Formula:C29H44O8
- Molecular Weight:520.65
IUPAC Name: 4-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
InChIKey: WQMLFJWIKARBFW-BKKMTDGVSA-N
SMILES: O[C@@]12[C@@]3([H])[C@@](CC[C@@]1([C@@H](C(CO4)=CC4=O)CC2)C)([H])[C@@]5([C@](C[C@H](CC5)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O)O)O)([H])CC3)C
Biological Activity: Evomonoside is a type of cardiac glycoside compound. Evomonoside exhibits significant in vitro anticancer activity, especially having nanomolar inhibitory concentrations against gastric cancer cell lines. Evomonoside has typical cardiac toxicity risks, including arrhythmias and conduction abnormalities. Evomonoside can be used for research on gastric cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Evomonoside | Evomonoside is a type of cardiac glycoside compound. Evomonoside exhibits significant in vitro anticancer activity, especially having nanomolar inhibitory concentrations against gastric cancer cell lines. Evomonoside has typical cardiac toxicity risks, including arrhythmias and conduction abnormalities. Evomonoside can be used for research on gastric cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
